Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00247273
Status:
COMPLETED
Last Update Posted:
2013-04-22
First Post:
2005-10-28
Brief Title:
A Study of Monthly Risedronate for Osteoporosis
Sponsor:
Warner Chilcott
Organization:
Warner Chilcott
Study Overview
Official Title:
A Phase III Multicenter Double-blind Randomized Active-controlled Parallel Group Non-inferiority Study Comparing 150 mg Risedronate Monthly With 5 mg Risedronate Daily in the Treatment of Postmenopausal Osteoporosis PMO
Status:
COMPLETED
Status Verified Date:
2013-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily
Detailed Description:
The comparator arms of this risedronate study are 150 mg monthly and 5 mg daily
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EFC6062 AND HMRF004M3001 | None | None | None |